{"id":9923,"date":"2024-02-11T10:22:51","date_gmt":"2024-02-11T09:22:51","guid":{"rendered":"https:\/\/www.afaf.asso.fr\/?p=9923"},"modified":"2024-02-11T16:27:05","modified_gmt":"2024-02-11T15:27:05","slug":"securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich","status":"publish","type":"post","link":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/","title":{"rendered":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Le nomlabofusp (anciennement CTI-1601) est une th\u00e9rapie de remplacement de la frataxine, en utilisant le couplage de la frataxine \u00e0 une prot\u00e9ine transporteuse. Les auteurs rapportent dans <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/acn3.51971\" target=\"_blank\" rel=\"noreferrer noopener\">cet article<\/a> les r\u00e9sultats des \u00e9tudes de phase 1 qui ont \u00e9valu\u00e9 la s\u00e9curit\u00e9, les profils pharmacocin\u00e9tiques et pharmacodynamiques du nomlabofusp administr\u00e9 par voie sous-cutan\u00e9e chez des adultes atteints d&#8217;ataxie de Friedreich<em>.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/acn3.51971\" target=\"_blank\" rel=\"noreferrer noopener\">En savoir plus<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le nomlabofusp (anciennement CTI-1601) est une th\u00e9rapie de remplacement de la frataxine, en utilisant le couplage de la frataxine \u00e0 une prot\u00e9ine transporteuse. Les auteurs rapportent dans cet article les r\u00e9sultats des \u00e9tudes de phase 1 qui ont \u00e9valu\u00e9 la s\u00e9curit\u00e9, les profils pharmacocin\u00e9tiques et pharmacodynamiques du nomlabofusp administr\u00e9 par voie sous-cutan\u00e9e chez des adultes [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":7805,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"ocean_front_end_style_editor":"no","ocean_post_layout":"","ocean_both_sidebars_style":"","ocean_both_sidebars_content_width":0,"ocean_both_sidebars_sidebars_width":0,"ocean_sidebar":"0","ocean_second_sidebar":"0","ocean_disable_margins":"enable","ocean_add_body_class":"","ocean_shortcode_before_top_bar":"","ocean_shortcode_after_top_bar":"","ocean_shortcode_before_header":"","ocean_shortcode_after_header":"","ocean_has_shortcode":"","ocean_shortcode_after_title":"","ocean_shortcode_before_footer_widgets":"","ocean_shortcode_after_footer_widgets":"","ocean_shortcode_before_footer_bottom":"","ocean_shortcode_after_footer_bottom":"","ocean_display_top_bar":"default","ocean_display_header":"default","ocean_header_style":"","ocean_center_header_left_menu":"0","ocean_custom_header_template":"0","ocean_custom_logo":0,"ocean_custom_retina_logo":0,"ocean_custom_logo_max_width":0,"ocean_custom_logo_tablet_max_width":0,"ocean_custom_logo_mobile_max_width":0,"ocean_custom_logo_max_height":0,"ocean_custom_logo_tablet_max_height":0,"ocean_custom_logo_mobile_max_height":0,"ocean_header_custom_menu":"0","ocean_menu_typo_font_family":"0","ocean_menu_typo_font_subset":"","ocean_menu_typo_font_size":0,"ocean_menu_typo_font_size_tablet":0,"ocean_menu_typo_font_size_mobile":0,"ocean_menu_typo_font_size_unit":"px","ocean_menu_typo_font_weight":"","ocean_menu_typo_font_weight_tablet":"","ocean_menu_typo_font_weight_mobile":"","ocean_menu_typo_transform":"","ocean_menu_typo_transform_tablet":"","ocean_menu_typo_transform_mobile":"","ocean_menu_typo_line_height":0,"ocean_menu_typo_line_height_tablet":0,"ocean_menu_typo_line_height_mobile":0,"ocean_menu_typo_line_height_unit":"","ocean_menu_typo_spacing":0,"ocean_menu_typo_spacing_tablet":0,"ocean_menu_typo_spacing_mobile":0,"ocean_menu_typo_spacing_unit":"","ocean_menu_link_color":"","ocean_menu_link_color_hover":"","ocean_menu_link_color_active":"","ocean_menu_link_background":"","ocean_menu_link_hover_background":"","ocean_menu_link_active_background":"","ocean_menu_social_links_bg":"","ocean_menu_social_hover_links_bg":"","ocean_menu_social_links_color":"","ocean_menu_social_hover_links_color":"","ocean_disable_title":"default","ocean_disable_heading":"default","ocean_post_title":"","ocean_post_subheading":"","ocean_post_title_style":"","ocean_post_title_background_color":"","ocean_post_title_background":0,"ocean_post_title_bg_image_position":"","ocean_post_title_bg_image_attachment":"","ocean_post_title_bg_image_repeat":"","ocean_post_title_bg_image_size":"","ocean_post_title_height":0,"ocean_post_title_bg_overlay":0.5,"ocean_post_title_bg_overlay_color":"","ocean_disable_breadcrumbs":"default","ocean_breadcrumbs_color":"","ocean_breadcrumbs_separator_color":"","ocean_breadcrumbs_links_color":"","ocean_breadcrumbs_links_hover_color":"","ocean_display_footer_widgets":"default","ocean_display_footer_bottom":"default","ocean_custom_footer_template":"0","ocean_post_oembed":"","ocean_post_self_hosted_media":"","ocean_post_video_embed":"","ocean_link_format":"","ocean_link_format_target":"self","ocean_quote_format":"","ocean_quote_format_link":"post","ocean_gallery_link_images":"on","ocean_gallery_id":[],"footnotes":""},"categories":[43],"tags":[],"class_list":["post-9923","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-informations_recherche","entry","has-media","owp-thumbs-layout-horizontal","owp-btn-normal","owp-tabs-layout-section","has-no-thumbnails"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"og:description\" content=\"Le nomlabofusp (anciennement CTI-1601) est une th\u00e9rapie de remplacement de la frataxine, en utilisant le couplage de la frataxine \u00e0 une prot\u00e9ine transporteuse. Les auteurs rapportent dans cet article les r\u00e9sultats des \u00e9tudes de phase 1 qui ont \u00e9valu\u00e9 la s\u00e9curit\u00e9, les profils pharmacocin\u00e9tiques et pharmacodynamiques du nomlabofusp administr\u00e9 par voie sous-cutan\u00e9e chez des adultes [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/\" \/>\n<meta property=\"og:site_name\" content=\"Association Fran\u00e7aise Ataxie de Friedreich\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-11T09:22:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-11T15:27:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3552\" \/>\n\t<meta property=\"og:image:height\" content=\"2365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline Gaboriau\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline Gaboriau\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/\"},\"author\":{\"name\":\"Caroline Gaboriau\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\"},\"headline\":\"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich\",\"datePublished\":\"2024-02-11T09:22:51+00:00\",\"dateModified\":\"2024-02-11T15:27:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/\"},\"wordCount\":81,\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"articleSection\":[\"Informations sur la recherche\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/\",\"name\":\"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"datePublished\":\"2024-02-11T09:22:51+00:00\",\"dateModified\":\"2024-02-11T15:27:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/12\\\/NEWS_actualite-scientifiques-e1741791418735.png\",\"width\":3552,\"height\":2362},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/2024\\\/02\\\/11\\\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"description\":\"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.afaf.asso.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#organization\",\"name\":\"Association Fran\u00e7aise Ataxie de Friedreich\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"contentUrl\":\"https:\\\/\\\/www.afaf.asso.fr\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/Logo-vert.png\",\"width\":1181,\"height\":709,\"caption\":\"Association Fran\u00e7aise Ataxie de Friedreich\"},\"image\":{\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.afaf.asso.fr\\\/#\\\/schema\\\/person\\\/7366aa03c1779ab28140e42231ed7b28\",\"name\":\"Caroline Gaboriau\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g\",\"caption\":\"Caroline Gaboriau\"},\"url\":\"https:\\\/\\\/www.afaf.asso.fr\\\/author\\\/caroline_gaboriau\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/","og_locale":"fr_FR","og_type":"article","og_title":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich","og_description":"Le nomlabofusp (anciennement CTI-1601) est une th\u00e9rapie de remplacement de la frataxine, en utilisant le couplage de la frataxine \u00e0 une prot\u00e9ine transporteuse. Les auteurs rapportent dans cet article les r\u00e9sultats des \u00e9tudes de phase 1 qui ont \u00e9valu\u00e9 la s\u00e9curit\u00e9, les profils pharmacocin\u00e9tiques et pharmacodynamiques du nomlabofusp administr\u00e9 par voie sous-cutan\u00e9e chez des adultes [&hellip;]","og_url":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/","og_site_name":"Association Fran\u00e7aise Ataxie de Friedreich","article_published_time":"2024-02-11T09:22:51+00:00","article_modified_time":"2024-02-11T15:27:05+00:00","og_image":[{"width":3552,"height":2365,"url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques.png","type":"image\/png"}],"author":"Caroline Gaboriau","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Caroline Gaboriau","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#article","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/"},"author":{"name":"Caroline Gaboriau","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28"},"headline":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich","datePublished":"2024-02-11T09:22:51+00:00","dateModified":"2024-02-11T15:27:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/"},"wordCount":81,"publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","articleSection":["Informations sur la recherche"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/","url":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/","name":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich - Association Fran\u00e7aise Ataxie de Friedreich","isPartOf":{"@id":"https:\/\/www.afaf.asso.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#primaryimage"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#primaryimage"},"thumbnailUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","datePublished":"2024-02-11T09:22:51+00:00","dateModified":"2024-02-11T15:27:05+00:00","breadcrumb":{"@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#primaryimage","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/12\/NEWS_actualite-scientifiques-e1741791418735.png","width":3552,"height":2362},{"@type":"BreadcrumbList","@id":"https:\/\/www.afaf.asso.fr\/2024\/02\/11\/securite-pharmacocinetique-et-pharmacodynamie-du-nomlabofusp-cti-1601-dans-lataxie-de-friedreich\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.afaf.asso.fr\/"},{"@type":"ListItem","position":2,"name":"S\u00e9curit\u00e9, pharmacocin\u00e9tique et pharmacodynamie du nomlabofusp (CTI-1601) dans l\u2019ataxie de Friedreich"}]},{"@type":"WebSite","@id":"https:\/\/www.afaf.asso.fr\/#website","url":"https:\/\/www.afaf.asso.fr\/","name":"Association Fran\u00e7aise Ataxie de Friedreich","description":"Association Fran\u00e7aise de l&#039;Ataxie de Friedreich","publisher":{"@id":"https:\/\/www.afaf.asso.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.afaf.asso.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.afaf.asso.fr\/#organization","name":"Association Fran\u00e7aise Ataxie de Friedreich","url":"https:\/\/www.afaf.asso.fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","contentUrl":"https:\/\/www.afaf.asso.fr\/wp-content\/uploads\/2022\/06\/Logo-vert.png","width":1181,"height":709,"caption":"Association Fran\u00e7aise Ataxie de Friedreich"},"image":{"@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.afaf.asso.fr\/#\/schema\/person\/7366aa03c1779ab28140e42231ed7b28","name":"Caroline Gaboriau","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8dbf8226706683015a2752bfbf4ecf0bea399e33452121cb9c1f4640fbea214f?s=96&d=mm&r=g","caption":"Caroline Gaboriau"},"url":"https:\/\/www.afaf.asso.fr\/author\/caroline_gaboriau\/"}]}},"_links":{"self":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/comments?post=9923"}],"version-history":[{"count":0,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/posts\/9923\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media\/7805"}],"wp:attachment":[{"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/media?parent=9923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/categories?post=9923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.afaf.asso.fr\/api-afaf\/wp\/v2\/tags?post=9923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}